Skip to main content
辰光医疗 logo

辰光医疗 — Investor Relations & Filings

Ticker · 920300 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2023-03-14 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920300

About 辰光医疗

http://www.shanghaicg.net/

Shanghai Chenguang Medical Technologies Co., Ltd. specializes in the research, development, and manufacturing of core components for Magnetic Resonance Imaging (MRI) systems. The product portfolio includes high-performance radiofrequency (RF) coils, superconducting magnets, and gradient coils designed for clinical, preclinical, and veterinary applications. The company focuses on high-field and ultra-high-field MRI technology, providing customized hardware solutions and integrated components to global imaging equipment manufacturers. Its technical capabilities encompass electromagnetic simulation, structural design, and precision manufacturing of specialized imaging hardware.

Recent filings

Filing Released Lang Actions
海通证券股份有限公司关于上海辰光医疗科技股份有限公司使用募集资金置换预先已投入募投项目及已支付发行费用的自筹资金的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a securities company (Haitong Securities) regarding the use of raised funds by Shanghai Chenguang Medical Technology Co., Ltd. It discusses the replacement of self-raised funds previously invested in projects and issuance expenses with the raised funds from a public stock issuance. The document references regulatory approvals, specific dates, amounts raised, and audit verification reports. It includes detailed financial figures and procedural approvals by the board and supervisory committee. The content is focused on the verification and audit of the use of raised funds rather than being a full annual or interim financial report. It is not a simple announcement or certification but a specialized audit-related verification report concerning the use of funds. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and verification opinions related to financial matters, excluding full annual reports or interim reports. The document length (2565 characters) is sufficient for a detailed audit opinion but not a full annual or interim report. Therefore, the classification is AR with high confidence. Q1 2023
2023-03-14 Chinese
海通证券股份有限公司关于上海辰光医疗科技股份有限公司使用募集资金向全资子公司借款实施募投项目的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special verification opinion by Haitong Securities regarding the use of raised funds by Shanghai Chenguang Medical Technology Co., Ltd. to lend to its wholly-owned subsidiary for investment projects. It includes specifics about the fundraising, use of funds, project progress, loan details, company information, decision-making procedures, and the sponsor's verification opinion. The document references regulatory approvals, fundraising dates, and compliance with securities regulations. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is not a simple announcement or certification but a detailed verification report related to the use of capital raised by the company. This fits the category of an Audit Report / Information (AR), as it involves a formal verification and audit opinion on the use of funds and compliance with regulations, distinct from the full annual report or other categories. Q1 2023
2023-03-14 Chinese
第四届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shanghai Chenguang Medical Technology Co., Ltd. It details the meeting date, attendance, and voting results on proposals related to the use of raised funds for loans to subsidiaries and replacement of funds for investment projects. It references related announcements on the Beijing Stock Exchange information disclosure platform but does not contain full financial statements or detailed financial data. The document is short (1299 characters) and primarily reports meeting resolutions and voting outcomes, not a full report or financial statement. It is not an Annual Report, Interim Report, or Earnings Release. It is not a Proxy Solicitation or Voting Results announcement since it is from the Supervisory Board and concerns internal resolutions rather than shareholder votes. It is not a Management or Board change announcement. The document fits best as a Regulatory Filing (RNS) because it is a formal regulatory disclosure of Supervisory Board meeting resolutions and related approvals without substantive financial data or report content.
2023-03-14 Chinese
关于使用募集资金向全资子公司提供借款实施募投项目的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Shanghai Chunguang Medical Technology Co., Ltd. regarding the use of raised funds to provide a loan to its wholly-owned subsidiary for implementing an investment project. It details the fundraising background, amounts raised, usage plans, and approvals by the board and supervisory committees. The document is a formal disclosure about the company's capital usage and financing activities related to the raised funds. It is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or a report publication announcement. The content fits best under the category of Capital/Financing Update (CAP), as it updates on the company's fundraising and capital usage activities.
2023-03-14 Chinese
独立董事关于第四届董事会第二十一次会议相关事项的事前认可意见及独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on specific board meeting matters related to the use of raised funds and internal approvals. It discusses the board meeting held on March 13, 2023, and provides independent opinions on proposals regarding the use of raised funds for loans to subsidiaries and replacement of self-raised funds. The document is a formal board/management announcement about internal decisions and approvals, not a full financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board opinions, not a report publication or regulatory filing.
2023-03-14 Chinese
关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Chenguang Medical Technology Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in projects and issuance expenses. It details the fundraising amount, approvals by the board and supervisory committee, independent director opinions, and verification reports by accounting firms. The document is a formal disclosure about the use of capital raised from a stock issuance and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release. It is a regulatory announcement about capital usage and compliance with relevant securities regulations. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3462 characters, which is consistent with an announcement rather than a full report.
2023-03-14 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.